Prognosis and Course of COVID-19 Infection in Hospitalised Patients

The aim of the cohort prospective observational study is to define the major factors influencing the course of COVID-19 infections and its prognosis in hospitalised patients.

The investigators plan to include 300 patients hospitalised with COVID-19 infection.

The phone contacts with patients are due after 90 and 180 days after discharge.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Covid19 COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections SARS-CoV Infection Severe Acute Respiratory Syndrome Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University Hospital #1, Moscow, Russia

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Hospitalisation with COVID-19

Exclusion criteria

History of hospitalisation with COVID-19 infection
Discharge from the hospital before the end of the treatment course
Transfer to another hospital

Treatment and study plan

Chitotriosidase activity

Diagnostic Test

The chitotriosidase activity will be measured in all the subjects

Primary outcomes

Need in biological therapy or/and respiratory support

Time frame: Up to 1 month

The primary endpoint is the need in biological therapy or/and respiratory support including noninvasive ventilation during hospital stay

Secondary outcomes

Number of days spent in hospital

Time frame: Up to 1 month

The investigators plan to assess the overall length of hospitalisation due to COVID-19 infection as an outcome measure
All-cause death

Time frame: 90 days

To assess the all-cause death 90 days after discharge
All-cause death

Time frame: 180 days

To assess the all-cause death 180 days after discharge

Sponsors and collaborators

Lead sponsor

I.M. Sechenov First Moscow State Medical University

Other

Registry information

Important dates

Study start: 2020
Primary completion: 2021
Study completion: 2023
First posted: Feb 12, 2021
Registry last updated: Jan 26, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed